| 1 |
Krishnamurthy S, Jain P, Tripathy D, Basset R, Randhawa R, Muhammad H, Huang W, Yang H, Kummar S, Wilding G, Roy R. Predicting Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy Using a Deep Convolutional Neural Network-Based Artificial Intelligence Tool. JCO Clin Cancer Inform 2023;7:e2200181. [PMID: 36961981 DOI: 10.1200/CCI.22.00181] [Reference Citation Analysis]
|
| 2 |
Qian Z, Chen L, Liu J, Jiang Y, Zhang Y. The emerging role of PPAR-alpha in breast cancer. Biomed Pharmacother 2023;161:114420. [PMID: 36812713 DOI: 10.1016/j.biopha.2023.114420] [Reference Citation Analysis]
|
| 3 |
Takabe K, Benesch MGK. Biomarker Research in World Journal of Oncology. World J Oncol 2023;14:1-3. [PMID: 36895990 DOI: 10.14740/wjon1577] [Reference Citation Analysis]
|
| 4 |
Oshi M, Patel A, Wu R, Le L, Tokumaru Y, Yamada A, Yan L, Matsuyama R, Ishikawa T, Endo I, Takabe K. Enhanced immune response outperform aggressive cancer biology and is associated with better survival in triple-negative breast cancer. NPJ Breast Cancer 2022;8:92. [PMID: 35945417 DOI: 10.1038/s41523-022-00466-2] [Reference Citation Analysis]
|
| 5 |
Rodrigues-Ferreira S, Nahmias C. Predictive biomarkers for personalized medicine in breast cancer. Cancer Lett 2022;545:215828. [PMID: 35853538 DOI: 10.1016/j.canlet.2022.215828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Xia H, Wang M, Su X, Lv Z, Yan Q, Guo X, Liu M. A Novel Gene Signature Associated With “E2F Target” Pathway for Predicting the Prognosis of Prostate Cancer. Front Mol Biosci 2022;9:838654. [DOI: 10.3389/fmolb.2022.838654] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Park S, Yi G. Development of Gene Expression-Based Random Forest Model for Predicting Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer. Cancers (Basel) 2022;14:881. [PMID: 35205629 DOI: 10.3390/cancers14040881] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Tokumaru Y, Oshi M, Huyser MR, Yan L, Fukada M, Matsuhashi N, Futamura M, Akao Y, Yoshida K, Takabe K. Low expression of miR-29a is associated with aggressive biology and worse survival in gastric cancer. Sci Rep 2021;11:14134. [PMID: 34239017 DOI: 10.1038/s41598-021-93681-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
